Genomic analysis of ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates from transplant unit
A retrospective cohort study analyzed 14 clinical isolates of ceftazidime/avibactam-resistant Klebsiella pneumoniae from the Mediterranean Institute for Transplants and Highly Specialized Therapies (ISMETT) in Palermo, Italy. This observational genomic characterization study examined isolates from a transplant unit setting, with no intervention, comparator, or clinical outcomes reported.
Most strains (exact proportion not reported) belonged to sequence type ST101 and carried blaKPC-31, blaKPC-3, or blaKPC-34 resistance genes, often with resistance-associated mutations. The analyzed strains revealed multidrug resistance patterns and frequent outer membrane protein alterations. Researchers also identified a significant spectrum of virulence genes and sequence type–specific plasmid replicons potentially involved in gene dissemination.
No safety, tolerability, or adverse event data were reported as this was an isolate analysis without patient-level information. The study has several limitations: small sample size (14 isolates), retrospective observational design, absence of clinical correlation data, and no information about patient outcomes, treatment, or infection control measures. Funding and conflicts of interest were not reported.
This genomic characterization provides descriptive data about resistance mechanisms in ceftazidime/avibactam-resistant Klebsiella pneumoniae from a transplant setting but offers no direct clinical practice guidance. The findings suggest concerning multidrug resistance patterns and virulence factors in this vulnerable population, warranting further investigation with clinical correlation studies.